Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. - Wikidata - wikimedia - TriplyDB

Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.

Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.

http://www.wikidata.org/entity/Q35362117

about

Rates of HCV Treatment Eligibility Among HCV-Monoinfected and HCV/HIV-Coinfected Patients in Tertiary Care Referral Centers Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons Diagnosis, management, and treatment of hepatitis C: an update Hepatitis B and hepatitis C co-infection in patients with HIV.Transcriptomic assay of CD8+ T cells in treatment-naïve HIV, HCV-mono-infected and HIV/HCV-co-infected Chinese.Hepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy.Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients.HCV chronic hepatitis in patients with HIV: clinical management issues.Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV.Hepatitis C and human immunodeficiency virus infection.HCV and HIV co-infection: mechanisms and management.Hepatitis C and HIV-1 coinfection.Therapeutic modalities in hepatitis C: challenges and development.The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre.Therapies for HIV and viral hepatitis coinfection.Coinfection with HIV and hepatitis C virus in injection drug users and minority populations.Delivering care to injection drug users coinfected with HIV and hepatitis C virus.

P2860

Q27491310-18D5D074-CB0A-4043-8553-7144D4D195DE Q28274676-F22E3431-9DE9-44CC-88A5-110D1BBA25C4 Q29619682-F711EE68-A350-4FE2-8864-9A618EA6FDE0 Q34323219-1CF4C2F9-A6C6-4484-A24F-F362146597EB Q34428339-9E273B05-EF2E-4CF4-ABCC-1038A8681FBA Q34536150-842D0758-52CE-45F0-BD18-E130FA54FC8E Q34631679-30E1B2CF-0FBA-47DB-B711-0689BEC0DE38 Q34756205-181AAE76-0B1F-4341-A721-31F871F96B4C Q34789841-903CB13D-1DFE-483A-80F9-CF90CFF45669 Q34984125-84655AED-D42D-48EA-B585-9993AFBB4766 Q35090634-A3362A6C-1058-43A4-9D17-BCE49D6E64A2 Q35595027-69C2AF30-3751-4945-90FD-9C16FA9FDA07 Q36011951-C7F87430-B2A7-4DA8-AC15-836C7B307728 Q36011960-46AF80D7-E11A-4334-96E7-7AA45B57C5C8 Q36066218-4FD2FFD2-5CB2-45F8-9397-0AB53D51938E Q36304424-C9E57D33-0F29-43BF-93F5-628E4D5E446D Q45497521-FAB47B03-1F59-47B6-B31A-62F0AB05471D

P2860

Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.

http://www.wikidata.org/entity/Q35362117

description

2000 nî lūn-bûn

@nan

2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Safety and efficacy of interfe ...... ted subjects: an early report.

@ast

Safety and efficacy of interfe ...... ted subjects: an early report.

@en

type

label

Safety and efficacy of interfe ...... ted subjects: an early report.

@ast

Safety and efficacy of interfe ...... ted subjects: an early report.

@en

prefLabel

Safety and efficacy of interfe ...... ted subjects: an early report.

@ast

Safety and efficacy of interfe ...... ted subjects: an early report.

@en

P1433

Q35362117-F60EE01E-740D-4DE4-B55B-B2F28DB0E185

P1476

Q35362117-0F3C110C-71FF-456D-934B-46B41CE50913

P2093

Q35362117-15AD21E2-1FFE-4936-AA8A-F970721DA975

Q35362117-41044210-5B08-40D8-BB80-1045FF7C5465

Q35362117-49C5D272-0B76-462D-8165-2321DE73113A

Q35362117-49F7A2BB-8E6D-4061-92FB-158A8CDD66A6

Q35362117-4C6D4FC2-1A39-4938-82D9-CE0FA06B2F73

Q35362117-5D98A39E-1542-487C-8321-CD4BB6A3AF45

Q35362117-94ED618E-1F93-40C7-972F-88C64EE16F12

Q35362117-CDC10C8C-7488-410C-9EAF-41A055659643

Q35362117-EE623DF9-DAB2-44D0-A2F6-6289F6635E2F

Q35362117-FB7F2FAE-22A5-4C41-9A7C-917CD138B7BF

P2860

Q35362117-09F8DF90-E7F8-4EF5-9C3E-A3ED183E5B33

Q35362117-10BB08F0-FA76-4BC1-9FCA-344D03816C91

Q35362117-1F595D00-F495-44E7-B2C3-1A1A13BB945B

Q35362117-3F819758-1125-4AC2-B93F-E4E5CD501386

Q35362117-47F859A3-557C-46E2-8D8D-EF29582FF690

Q35362117-4A8A8854-6312-49C9-ACBA-3477F8C5A851

Q35362117-59DDFA66-26B8-48BA-B4C6-36EB20804C22

Q35362117-8E032EA6-F334-4D59-A800-A1606CB61DDB

Q35362117-961FA355-0F3A-45C7-814F-6A1B167030F8

Q35362117-D10770FF-1861-49C8-801C-155A07F81D99

P304

Q35362117-2C4CB6BE-2F6F-49F2-88A9-23CF672AC937

P31

Q35362117-F2A52F8E-94C3-481F-826E-5B8C0320C8DA

P356

Q35362117-4D72BFC2-CF41-4270-93C8-5EA07891C69B

P407

Q35362117-E62135D4-C6A2-45E7-AFC0-3E35C7765881

P433

Q35362117-024B5E91-D759-4487-A233-E72D758D20E9

P478

Q35362117-921F6926-CABC-4F47-AB26-266109C7D9E0

P50

Q35362117-885660C2-5066-4914-8B40-DE89639F68F7

Q35362117-C20038D7-A48C-4CD4-AEEA-AA3BE0184CE2

P577

Q35362117-A4A98E14-9E10-4B4F-98AA-578C9587C669

P698

Q35362117-BB39D6C4-70BC-464A-8D42-A735B7322262

P932

Q35362117-4CBAB4B1-6990-40FC-9BAA-33775CE106F8

P356

P1433

P1476

Safety and efficacy of interfe ...... ted subjects: an early report.

@en

P2093

Benhamou Y

http://www.w3.org/2001/XMLSchema#string

Bochet M

http://www.w3.org/2001/XMLSchema#string

Bréchot C

http://www.w3.org/2001/XMLSchema#string

Chaix ML

http://www.w3.org/2001/XMLSchema#string

Fontaine H

http://www.w3.org/2001/XMLSchema#string

Lagneaux JL

http://www.w3.org/2001/XMLSchema#string

Landau A

http://www.w3.org/2001/XMLSchema#string

Pialoux G

http://www.w3.org/2001/XMLSchema#string

Pol S

http://www.w3.org/2001/XMLSchema#string

Zylberberg H

http://www.w3.org/2001/XMLSchema#string

P2860

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

Ribavirin antagonizes the effect of azidothymidine on HIV replication

Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro.

Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections.

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.

Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users.

A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy: virologic observations. Ribavirin-LAS Collaborative Group.

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

P304

694-697

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.47.5.694

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P50

Thierry Poynard

Christine Katlama

P577

2000-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11034587

http://www.w3.org/2001/XMLSchema#string

P932

1728127

http://www.w3.org/2001/XMLSchema#string